Clinical Trials Browser

OTHER × Triple Negative Breast Neoplasms × apatinib × Clear all

NCT05582499 2026-05-28

FASCINATE-N

Phase 2 Recruiting

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT05192798 2025-02-27

Albumin-Bound Paclitaxel Combined With Antiangiogenic Agents in First-line Treatment of Relapsed or Metastatic TNBC

Phase 2 Recruiting

Triple Negative Breast Neoplasms

NCT05447702 2023-05-22

Study of Camrelizumab Plus Apatinib and Chemotherapy as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC)

Phase 2 Recruiting

Triple Negative Breast Neoplasms

NCT05556200 2023-04-12

A Phase II Trial of Camrelizumab in Combination With Apatinib for Neoadjuvant Treatment of Early-stage TNBC With a High Proportion of TILs

Phase 2 Unknown

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT03805399 2022-08-10

FUTURE

Phase 1/2 Unknown

Triple Negative Breast Neoplasms

NCT03243838 2022-02-02

LANCET

Phase 2 Completed

Triple Negative Breast Neoplasms

NCT03932526 2019-04-30

Combined Use of Apatinib Mesylate and Vinorelbine Versus Single Use of Vinorelbine in Triple-negative Breast Cancer

Phase 2 Unknown

Triple Negative Breast Neoplasms

NCT03775928 2018-12-14

Compare Apatinib Plus Capecitabine Versus Capecitabine in Maintenance Therapy for Patients With Advanced Triple-negative Breast Cancer

Phase 2 Unknown

Triple Negative Breast Neoplasms

NCT03348098 2017-11-28

Clinical Study of Neoadjuvant Therapy With Apatinib and Paclitaxel in Local Advanced Triple-negative Breast Cancer

Phase 2 Unknown

Triple Negative Breast Neoplasms

NCT01176669 2015-09-09

Study of Apatinib in Metastatic Triple-Negative Breast Cancer Patients

Phase 2 Completed

Breast Neoplasms, Triple Negative Breast Neoplasms